Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 290

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Open access
Schindler, Suzanne E., Galasko, Douglas, Pereira, Ana C., Rabinovici, Gil D., Salloway, Stephen, Suárez-Calvet, Marc, Khachaturian, Ara S., Mielke, Michelle M., Udeh-Momoh, Chi, Weiss, Joan, Batrla, Richard, Bozeat, Sasha, Dwyer, John R., Holzapfel, Drew, Jones, Daryl Rhys, Murray, James F., Partrick, Katherine A., Scholler, Emily, Vradenburg, George, Young, Dylan, Algeciras-Schimnich, Alicia, Aubrecht, Jiri, Braunstein, Joel B., Hendrix, James, Hu, Yan Helen, Mattke, Soeren, Monane, Mark, Reilly, David, Somers, Elizabeth, Teunissen, Charlotte E., Shobin, Eli, Vanderstichele, Hugo, Weiner, Michael W., Wilson, David, Hansson, Oskar·2024·Nature Reviews Neurology

Abstract

Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance. The Global CEO Initiative on Alzheimer’s Disease convened a BBM Workgroup to consider the minimum acceptable performance of BBM tests for clinical use. Amyloid PET status was identified as the reference standard. For use as a triaging test before subsequent confirmatory tests such as amyloid PET or CSF tests, the BBM Workgroup recommends that a BBM test has a sensitivity of ≥90% with a specificity of ≥85% in primary care and ≥75–85% in secondary care depending on the availability of follow-up testing. For use as a confirmatory test without follow-up tests, a BBM test should have performance equivalent to that of CSF tests — a sensitivity and specificity of ~90%. Importantly, the predictive values of all biomarker tests vary according to the pre-test probability of amyloid pathology and must be interpreted in the complete clinical context. Use of BBM tests that meet these performance standards could enable more people to receive an accurate and timely Alzheimer disease diagnosis and potentially benefit from new treatments. Anti-amyloid treatments for early symptomatic Alzheimer disease have greatly increased the need for biomarker confirmation of amyloid pathology and blood biomarker tests offer an accessible and scalable biomarker test. This Consensus Statement provides recommendations for the minimum acceptable performance of blood biomarker tests for clinical use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-024-00977-5

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 94 references

Cited by

See all 290

Metadata

Authors
Schindler, S. E., Galasko, D., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez-Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh-Momoh, C., Weiss, J., Batrla, R., Bozeat, S., Dwyer, J. R., Holzapfel, D., Jones, D. R., Murray, J. F., Partrick, K. A., Scholler, E., Vradenburg, G., Young, D., Algeciras-Schimnich, A., Aubrecht, J., Braunstein, J. B., Hendrix, J., Hu, Y. H., Mattke, S., Monane, M., Reilly, D., Somers, E., Teunissen, C. E., Shobin, E., Vanderstichele, H., Weiner, M. W., Wilson, D., & Hansson, O.
Venue
Nature Reviews Neurology
Published
2024-06-12
Volume
20
Issue
7
Pages
426-439
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W4399571087
Cited by
290
References
94
FWCI
29.37
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease. https://app.cochat.ai/papers/10.1038/s41582-024-00977-5
The paper
Schindler, S. E., Galasko, D., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez-Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh-Momoh, C., Weiss, J., Batrla, R., Bozeat, S., Dwyer, J. R., Holzapfel, D., Jones, D. R., Murray, J. F., Partrick, K. A., Scholler, E., Vradenburg, G., . . . Hansson, O. (2024). Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease. Nature Reviews Neurology. https://doi.org/10.1038/s41582-024-00977-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.